March 17, 2022

InSysBio team is going to present its posters in frames of American Association for Cancer Research (AACR) Annual Meeting 2022 which is to be held April 8-13, New Orleans, Louisiana. The abstracts have been published on AACR website and E-Posters are going to be presented if frames of Poster Sessions:

April 8, 2022, 12:00 PM - 1:00 PM

(Session OPO.ET05.01 - Pharmacology, Pharmacogenetics, and Pharmacogenomics)

• 5421 - "Prediction of intratumoral TIGIT receptor occupancy after the treatment with anti-TIGIT antibodies" by Dmitry Shchelokov¹, Oleg Demin Jr¹, Oleg Demin¹, Ahsan Rizwan², Yun Zhang³, Wei Tan⁴, Srikumar Sahasranaman², Nageshwar Budha²

Affiliation: (1) InSysBio, Moscow, Russia; (2) BeiGene USA, Inc., San Mateo, CA; (3) BeiGene (Beijing) Co., Ltd. Beijing, China; (4) BeiGene (Shanghai) Co., Ltd., Shanghai, China

(Session OPO.BCS02.01 - Convergence Science and Systems Biology)

• 5049 - "Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1" by Alexandra Diakonova, Oleg Demin Jr., Dmitry Shchelokov, Oleg Demin

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

Share